Working with TipRanks
Follow Us
Stocks
ETFs
Options
Commodities
Crypto
Currency
Research Tools
Calendars
Economic Indicators
Calculators
Education
About Us
Working with TipRanks
Follow Us
Liquidia Technologies Inc (LQDA)
NASDAQ:LQDA
RESEARCH TOOLSreports
Liquidia Technologies (LQDA) Stock Price & Analysis
420 Followers
LQDA Stock Chart & Stats
Day’s Range$0 - $0
52-Week Range$5.71 - $16.99
Previous Close$13.58
Volume341.56K
Average Volume (3M)907.39K
Market Cap
$1.05B
Enterprise Value$959.88M
Total Cash (Recent Filing)$83.68M
Total Debt (Recent Filing)$3.50M
Price to Earnings (P/E)-11.2
Beta0.35
Next Earnings
May 09, 2024EPS Estimate
-$0.32Next Dividend Ex-DateN/A
Dividend YieldN/A
Share Statistics
EPS (TTM)-1.21
Shares Outstanding76,027,776
10 Day Avg. Volume713,425
30 Day Avg. Volume907,386
Standard Deviation0.21
R-Squared0.00158
Alpha0.02
Financial Highlights & Ratios
Price to Book (P/B)26.03
Price to Sales (P/S)59.04
Price to Cash Flow (P/CF)-16.30
P/FCF Ratio0.00
Enterprise Value/Market CapN/A
Enterprise Value/Revenue54.89
Enterprise Value/Gross Profit65.75
Enterprise Value/Ebitda-13.70
Forecast
1Y Price Target
$22.40Price Target Upside63.32% Upside
Rating ConsensusModerate Buy
Number of Analyst Covering5
Liquidia Technologies News
Bulls Say, Bears Say
Bulls Say
Financial OutlookAnalyst maintains a Buy rating and raises price target to $32, reflecting the potential for near-term commercial growth for Yutrepia.
Market DynamicsInhaled treprostinil expected to continue taking market share from oral and injected segments, positioning YUTREPIA as a preferred treatment option.
Regulatory MilestoneCleared path to timely FDA approval for Yutrepia can remove remaining launch uncertainties.
Bears Say
Legal RisksOngoing patent litigation with United Therapeutics poses risks to the timeline for FDA approval of YUTREPIA.
Market CompetitionLiquidia faces a limited market opportunity for YUTREPIA due to Tyvaso DPI's dominance and lack of clear differentiation.
Regulatory ChallengesThe FDA's delay in approving YUTREPIA for a PH-ILD indication adds uncertainty and concerns for potential longer delays.
---
Ownership Overview
67.81% Insiders
6.14% Mutual Funds
7.12% Other Institutional Investors
18.93% Public Companies and
Individual Investors
Risk Analysis
Main Risk Category
Tech & InnovationRisks related to the company’s reliance on technology and ability to make innovative products
Website Traffic
Sorry, No Data AvailableThere is no website visitor data available for this stock.
---
LQDA FAQ
What was Liquidia Technologies Inc’s price range in the past 12 months?
Liquidia Technologies Inc lowest stock price was $5.71 and its highest was $16.99 in the past 12 months.
What is Liquidia Technologies Inc’s market cap?
Currently, no data Available
When is Liquidia Technologies Inc’s upcoming earnings report date?
Liquidia Technologies Inc’s upcoming earnings report date is May 09, 2024 which is in 20 days.
How were Liquidia Technologies Inc’s earnings last quarter?
Liquidia Technologies Inc released its earnings results on Mar 13, 2024. The company reported -$0.43 earnings per share for the quarter, missing the consensus estimate of -$0.237 by -$0.193.
Is Liquidia Technologies Inc overvalued?
According to Wall Street analysts Liquidia Technologies Inc’s price is currently Undervalued.
Does Liquidia Technologies Inc pay dividends?
Liquidia Technologies Inc does not currently pay dividends.
What is Liquidia Technologies Inc’s EPS estimate?
Liquidia Technologies Inc’s EPS estimate is -$0.32.
How many shares outstanding does Liquidia Technologies Inc have?
Liquidia Technologies Inc has 76,027,780 shares outstanding.
What happened to Liquidia Technologies Inc’s price movement after its last earnings report?
Liquidia Technologies Inc reported an EPS of -$0.43 in its last earnings report, missing expectations of -$0.237. Following the earnings report the stock price went up 5.365%.
Which hedge fund is a major shareholder of Liquidia Technologies Inc?
Among the largest hedge funds holding Liquidia Technologies Inc’s share is Fortitude Family Office, LLC. It holds Liquidia Technologies Inc’s shares valued at 26K.
---
Liquidia Technologies Stock Smart Score
Neutral
1
2
3
4
5
6
7
8
9
10
Analyst Consensus
Moderate Buy
Average Price Target:
$22.40 (63.32% Upside)
$22.40 (63.32% Upside)
Blogger Sentiment
Bullish
LQDA Sentiment 100%
Sector Average 70%
Sector Average 70%
Hedge Fund Trend
Increased
By 2.2K Shares
Last Quarter.
Last Quarter.
Crowd Wisdom
Very Negative
Last 7 Days ▲ 0.4%
Last 30 Days ▼ 6.0%
Last 30 Days ▼ 6.0%
Technicals
SMA
Positive
20 days / 200 days
Momentum
100.88%
12-Months-Change
Fundamentals
Return on Equity
-114.01%
Trailing 12-Months
Asset Growth
-8.31%
Trailing 12-Months
Company Description
Liquidia Technologies Inc
Liquidia Technologies, Inc. is a clinical biopharmaceutical company focused on the development and commercialization of human therapeutics using its proprietary PRINT technology to transform the lives of patients. It operates in two segments: Pharmaceutical Products and Partnering & Licensing. The two product candidates from its pipeline: LIQ861 for the treatment of pulmonary arterial hypertension and LIQ865 for the treatment of local post-operative pain. Liquidia Technologies was founded in 2004 and is headquartered in Durham, NC.
---
LQDA Earnings Call
Q4 2024
0:00 / 0:00
---
LQDA Stock 12 Months Forecast
Average Price Target
$22.40
▲(63.32% Upside)
Technical Analysis
Voyager Therapeutics
―
Lexicon Pharmaceuticals
―
Fate Therapeutics
―
Crispr Therapeutics AG
―
Best Analysts Covering LQDA
1 Year
1 Year Success Rate
13/15 ratings generated profit
1 Year Average Return
+58.29%
reiterated a buy rating 18 days ago
Copying Julian Harrison's trades and holding each position for 1 Year would result in 86.67% of your transactions generating a profit, with an average return of +58.29% per trade.
---